Geron Corp (GERN)

$1.39 +0.19 (15.83%)
Market Cap 764.30M
Revenue (ttm) 76.99M
Net Income (ttm) -174.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.74%
Debt to Equity Ratio 0.44
Volume 28,406,898
Avg Vol 10,138,864
Day's Range N/A - N/A
Shares Out 636.92M
Stochastic %K 46%
Beta 0.73
Analysts Sell
Price Target $3.39

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 473 7700
Address:
919 East Hillsdale Boulevard, Suite 250, Foster City, United States
share97
share97 Aug. 7 at 7:44 AM
$GERN shorties scrambling to file by tomorrow. Chance the trash case will be dismissed afterwards lol
0 · Reply
d_risk
d_risk Aug. 7 at 1:05 AM
$GERN - Geron Corporation Common Stock - 10Q - Updated Risk Factors Geron’s 10-Q risk update for 2025 sharpens focus on RYTELO’s U.S./EU regulatory and commercialization challenges, including post-market commitments, manufacturing risks, reimbursement hurdles, IP protection complexities, financing needs, leadership changes, and heightened litigation and compliance exposures—all threatening growth and financial stability. #Biotechnology #LitigationRisk #LeadershipChanges #FinancingNeeds #IntellectualProperty #ReimbursementIssues #ManufacturingRisks #RegulatoryChallenges 🟢 Added 🟠 Removed https://d-risk.ai/GERN/10-Q/2025-08-06
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 6 at 11:46 PM
$GERN Volume precedes price action YET again - 20% stress free gainer here
0 · Reply
mergingcultures
mergingcultures Aug. 6 at 8:59 PM
$GERN we know this can sell, so lets go
0 · Reply
biopuzzle
biopuzzle Aug. 6 at 8:52 PM
$GERN and here we have it: beautiful green solid candle on the close!
0 · Reply
BreezyAngel21424
BreezyAngel21424 Aug. 6 at 8:45 PM
$GERN 1.40 AH...LFG
0 · Reply
Akwaba76
Akwaba76 Aug. 6 at 8:17 PM
$GERN Harout Semerjian has a clear track record of steering companies through acquisitions, notably: Immunomedics: Served as CEO shortly before it was acquired by Gilead for $21 billion in 2020. GlycoMimetics: His departure coincided with GlycoMimetics entering a merger agreement with Crescent Biopharma in 2025. 🧭 Pattern: He’s often brought in during late-stage or commercial transition phases, and his skillset aligns with positioning companies for acquisition — either by streamlining operations, increasing valuation via commercialization, or driving late-stage trial success
1 · Reply
SmashDipRoll
SmashDipRoll Aug. 6 at 8:17 PM
$GERN gap at 2.4 with an option on a few days dte. You will balance me out.
0 · Reply
GildedAge01
GildedAge01 Aug. 6 at 8:16 PM
$GERN WHAT??!! Come on GERN
0 · Reply
TToks
TToks Aug. 6 at 7:37 PM
$GERN
0 · Reply
Latest News on GERN
Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:01 PM EDT - 12 hours ago

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:01 AM EDT - 20 hours ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Aug 6, 2025, 7:00 AM EDT - 20 hours ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 28, 2025, 8:00 AM EDT - 9 days ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:05 PM EDT - 19 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Conservative Vision Of A Positive Future For Geron

Jun 3, 2025, 9:57 AM EDT - 2 months ago

Conservative Vision Of A Positive Future For Geron

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025, 8:30 AM EDT - 2 months ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

May 9, 2025, 8:28 AM EDT - 3 months ago

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 8, 2025, 11:24 PM EDT - 3 months ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:50 PM EDT - 3 months ago

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 12:33 PM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 3 months ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 24, 2025, 9:33 PM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 18, 2025, 4:30 PM EDT - 3 months ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 9, 2025, 10:40 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31, 2025, 4:32 PM EDT - 4 months ago

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 4:30 PM EDT - 4 months ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 4 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS LLY NVO SEPN

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

Mar 22, 2025, 12:31 PM EDT - 4 months ago

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

TBBK

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17, 2025, 5:19 PM EDT - 5 months ago

Geron Corp: How Concerned Should We Be About Rytelo Sales?

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Mar 17, 2025, 7:42 AM EDT - 5 months ago

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Mar 14, 2025, 3:04 PM EDT - 5 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Mar 11, 2025, 4:30 PM EDT - 5 months ago

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Geron Corporation Announces Departure of Chief Executive Officer

Mar 11, 2025, 4:02 PM EDT - 5 months ago

Geron Corporation Announces Departure of Chief Executive Officer

share97
share97 Aug. 7 at 7:44 AM
$GERN shorties scrambling to file by tomorrow. Chance the trash case will be dismissed afterwards lol
0 · Reply
d_risk
d_risk Aug. 7 at 1:05 AM
$GERN - Geron Corporation Common Stock - 10Q - Updated Risk Factors Geron’s 10-Q risk update for 2025 sharpens focus on RYTELO’s U.S./EU regulatory and commercialization challenges, including post-market commitments, manufacturing risks, reimbursement hurdles, IP protection complexities, financing needs, leadership changes, and heightened litigation and compliance exposures—all threatening growth and financial stability. #Biotechnology #LitigationRisk #LeadershipChanges #FinancingNeeds #IntellectualProperty #ReimbursementIssues #ManufacturingRisks #RegulatoryChallenges 🟢 Added 🟠 Removed https://d-risk.ai/GERN/10-Q/2025-08-06
0 · Reply
PhishTourFunds
PhishTourFunds Aug. 6 at 11:46 PM
$GERN Volume precedes price action YET again - 20% stress free gainer here
0 · Reply
mergingcultures
mergingcultures Aug. 6 at 8:59 PM
$GERN we know this can sell, so lets go
0 · Reply
biopuzzle
biopuzzle Aug. 6 at 8:52 PM
$GERN and here we have it: beautiful green solid candle on the close!
0 · Reply
BreezyAngel21424
BreezyAngel21424 Aug. 6 at 8:45 PM
$GERN 1.40 AH...LFG
0 · Reply
Akwaba76
Akwaba76 Aug. 6 at 8:17 PM
$GERN Harout Semerjian has a clear track record of steering companies through acquisitions, notably: Immunomedics: Served as CEO shortly before it was acquired by Gilead for $21 billion in 2020. GlycoMimetics: His departure coincided with GlycoMimetics entering a merger agreement with Crescent Biopharma in 2025. 🧭 Pattern: He’s often brought in during late-stage or commercial transition phases, and his skillset aligns with positioning companies for acquisition — either by streamlining operations, increasing valuation via commercialization, or driving late-stage trial success
1 · Reply
SmashDipRoll
SmashDipRoll Aug. 6 at 8:17 PM
$GERN gap at 2.4 with an option on a few days dte. You will balance me out.
0 · Reply
GildedAge01
GildedAge01 Aug. 6 at 8:16 PM
$GERN WHAT??!! Come on GERN
0 · Reply
TToks
TToks Aug. 6 at 7:37 PM
$GERN
0 · Reply
ZoeyTanner
ZoeyTanner Aug. 6 at 7:33 PM
$GERN One year ago, we were 4.84..We have a long long road ahead. We fell into a "burning ring of Fire", as per Johnny
0 · Reply
ShortWeak
ShortWeak Aug. 6 at 7:32 PM
$GERN .... What??? Gercon is up 16 cents??? 😂
1 · Reply
nadruss2001
nadruss2001 Aug. 6 at 7:25 PM
$GERN decent volume
0 · Reply
mar99
mar99 Aug. 6 at 7:17 PM
$GERN Needham and TD Cowen reiterate Buy rating and price targets on strong results.
1 · Reply
LongBallBarn
LongBallBarn Aug. 6 at 6:26 PM
$GERN
0 · Reply
Polip
Polip Aug. 6 at 6:02 PM
$GERN 3 is inevitable
1 · Reply
Mail_Dog
Mail_Dog Aug. 6 at 6:01 PM
$GERN Keep increasing sales & revenue & imo we’ll be back over $3 in no time..!!
1 · Reply
dojidad
dojidad Aug. 6 at 5:50 PM
$GERN Congrats to anyone who made money today, that is awesome. For me, the next possible entry would be over the 50-day (red line). Looking at the minute chart, unless some catalyst happens, this should close between 1.31-1.36, with a possible high of 1.41. I'll do some DD and if it trends over the 50, consider an entry. Have a great rest of the day (or night, depending where you are).
1 · Reply
Taz69
Taz69 Aug. 6 at 5:41 PM
$GERN New CEO, Harout Semerjian previously worked for Novantis, it's not a coincidence!
0 · Reply
Hdheheh
Hdheheh Aug. 6 at 5:33 PM
$GERN I am right once again! Don’t ever doubt me
0 · Reply
Ruzmadji
Ruzmadji Aug. 6 at 4:40 PM
$GERN will pop soon! LMAO
0 · Reply
Cello69
Cello69 Aug. 6 at 3:55 PM
$GERN Added 7500 $1.31
0 · Reply